Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004)

Area of Science:

• Immunology
• Rheumatology
• Oncology

Background:

• Rituximab targets CD20-expressing B-lymphocytes, a mechanism relevant to autoimmune disease pathogenesis.
• B-cell regulation plays a crucial role in autoimmune conditions, prompting exploration of rituximab beyond lymphoma treatment.
• Patients with autoimmune diseases refractory to conventional therapies may benefit from novel treatment approaches.

Purpose of the Study:

• To evaluate the short-term efficacy and tolerance of rituximab in patients with various autoimmune diseases.
• To assess rituximab's safety profile in a cohort of patients with refractory autoimmune conditions.
• To explore rituximab's potential in treating autoimmune diseases not previously managed with this agent.

Main Methods:

• Retrospective evaluation of 29 patients treated with rituximab (375 mg/m2 for 4 weeks or 2x1g doses) between 2002-2004.
• Inclusion of patients with diverse autoimmune diseases refractory to standard treatments.
• Monitoring for treatment efficacy, tolerance, and adverse events.

Main Results:

• Remarkable short-term efficacy observed in most patients, with one exception (thrombocytopenic purpura).
• Successful treatment outcomes reported in two cases with rare conditions: hypergammaglobulinemic purpura of Waldenstrom and eosinophilic fasciitis.
• Treatment was well-tolerated, with no unexpected adverse events and a significant reduction in steroid dosage.

Conclusions:

• Rituximab demonstrates safety and effectiveness for treating various autoimmune diseases resistant to other treatments.
• The anti-CD20 monoclonal antibody offers a viable therapeutic option for refractory autoimmune conditions.
• Further investigation into rituximab's role in autoimmune disease management is warranted.